Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single-centre experience.
Alicia Roldán PérezJuan Andrés Vázquez PaganiniM José Penalva MorenoEugenio Giménez MesaAlba Sara Vilches MorenoClaudia Nuñez-Torrón StockRegina Herráez GarcíaPublished in: Clinical case reports (2022)
We report our experience with venetoclax/hypomethylating agents (Ven/HMA) in 8 AML patients not candidates for intensive CT or refractory/relapsed with limited treatment options. The response rate was 50%. Venetoclax was well-tolerated in 62.5% of the patients. Ven/HMA provides a benefit particularly when used in patients without prior HMA exposure.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- acute myeloid leukemia
- acute lymphoblastic leukemia
- magnetic resonance imaging
- computed tomography
- squamous cell carcinoma
- patient reported outcomes
- radiation therapy
- diffuse large b cell lymphoma
- magnetic resonance
- pet ct
- allogeneic hematopoietic stem cell transplantation